|
|
Volumn 31, Issue 30, 2013, Pages 3746-3748
|
|
Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: Tivozanib as a case study
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
TIVOZANIB;
ANTINEOPLASTIC AGENT;
CARBANILAMIDE DERIVATIVE;
NICOTINAMIDE;
QUINOLINE DERIVATIVE;
DRUG DERIVATIVE;
CANCER CHEMOTHERAPY;
CANCER GROWTH;
CANCER PATIENT;
CANCER SURVIVAL;
CAUSE OF DEATH;
DETERIORATION;
DRUG APPROVAL;
EDITORIAL;
HUMAN;
KIDNEY CANCER;
KIDNEY CELL CANCER;
METASTASIS;
MONOTHERAPY;
OVERALL SURVIVAL;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
QUALITY OF LIFE;
ADJUVANT THERAPY;
ANALOGS AND DERIVATIVES;
CARCINOMA, RENAL CELL;
FEMALE;
KIDNEY NEOPLASMS;
MALE;
PROCEDURES;
KIDNEY CARCINOMA;
KIDNEY TUMOR;
METHODOLOGY;
NOTE;
ANTINEOPLASTIC AGENTS;
CARCINOMA, RENAL CELL;
FEMALE;
HUMANS;
KIDNEY NEOPLASMS;
MALE;
NEOADJUVANT THERAPY;
NIACINAMIDE;
PHENYLUREA COMPOUNDS;
QUINOLINES;
|
|
EID: 84891543168
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2013.51.4869 Document Type: Editorial |
|
Times cited : (9)
|
|
References (3)
|
